Amines, leur utilisation et leur préparation

Amine, ihre Verwendung und Herstellung

New amines, their use and preparation

Abstract

Novel 3,3-diphenylpropylamines of formula I wherein R¹ signifies hydrogen or methyl, R², R³ and R⁴ independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphanoyl or halogen, and X represents a tertiary amino group -NR⁵,R⁶, wherein R⁵ and R⁶ signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and which may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the com­pounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers, their use as drugs, especially as anti­cholinergic agents, their use for preparing an anticholinergic drug, pharmaceutical compositions containing the novel amines, and methods for preparing the same.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (4)

    Publication numberPublication dateAssigneeTitle
    DK-111894-ADecember 31, 1969
    GB-1169944-ANovember 05, 1969Geistlich Soehne AgNovel 3,3-Diphenylpropylamines and processes for the preparation thereof
    GB-1169945-ANovember 05, 1969Geistlich Soehne AgPharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
    US-3446901-AMay 27, 1969Geistlich Soehne AgAntidepressant compositions containing diphenylpropylamine derivatives

NO-Patent Citations (1)

    Title
    CHEMICAL ABSTRACTS, Vol. 97, No. 15, 11 October 1982, page 20, No. 120105n, Columbus, Ohio, US; MARKARYAN E. et al.: "Study of the Relationship between Permeability of Arylalkylamine Derivatives across a Semipermeable Membrane and their Antiadrenergic Activity" & Biol. Zh. Arm. 1982, 35(2), 101-7 (Russ); Abstract.

Cited By (50)

    Publication numberPublication dateAssigneeTitle
    CN-102329244-AJanuary 25, 2012凯瑞斯德生化(苏州)有限公司一种rs-托特罗定的制备方法及中间体化合物
    DE-10028443-C1May 29, 2002Sanol Arznei Schwarz GmbhProduction of optically active 3,3-diaryl-propylamine derivatives comprises six step process from 4-hydroxybenzoic acid or alkyl 4-hydroxybenzoate and cinnamic acid
    EP-0924983-A1June 30, 1999Gunnar AbergS(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
    EP-0924983-A4August 25, 1999Gunnar AbergS(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
    EP-1633695-A2March 15, 2006Bridge Pharma, Inc.Agents spasmolytiques pour muscles lisses
    EP-1633695-A4December 12, 2007Bridge Pharma IncAgents spasmolytiques pour muscles lisses
    EP-1693361-A1August 23, 2006Dipharma S.p.A.Un procédé pour la préparation de toltérodine
    EP-1810962-A1July 25, 2007Dipharma Francis S.r.l.Verfahren zur Reinigung von Tolterodin
    EP-1964553-A1September 03, 2008KRKA, D.D., Novo MestoComposition pharmaceutique de toltérondine à libération modifiée
    US-6114549-ASeptember 05, 2000Smithkline Beecham CorporationProcess of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
    US-6310103-B1October 30, 2001Bridge Pharma, Inc.S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
    US-6441173-B1August 27, 2002Smithkline Beecham CorporationProcess for preparing indane carboxylate and cyclopentano [6] pyridine derivatives
    US-6809214-B2October 26, 2004Schwartz Pharma AgShortened synthesis of 3,3-diarylpropylamine derivatives
    US-7230030-B2June 12, 2007Schwarz Pharma AgDerivatives of 3,3-diphenylpropylamines
    US-7232835-B2June 19, 2007Ranbaxy Laboratories Limited3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
    US-7265147-B2September 04, 2007Ranbaxy Laboratories Limited3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
    US-7288562-B2October 30, 2007Ranbaxy Laboratories LimitedFluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
    US-7384980-B2June 10, 2008Schwarz Pharma AgDerivatives of 3,3-diphenylpropylamines
    US-7393874-B2July 01, 2008Hetero Drugs LimitedPolymorphs of tolterodine tartrate
    US-7399779-B2July 15, 2008Ranbaxy Laboratories Limited3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
    US-7410993-B2August 12, 2008Ranbaxy Laboratories Limited3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
    US-7446123-B2November 04, 2008Ranbaxy Laboratories LimitedAzabicyclo derivatives as muscarinic receptor antagonists
    US-7465751-B2December 16, 2008Ranbaxy Laboratories Limited1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
    US-7488748-B2February 10, 2009Ranbaxy Laboratories Limited3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    US-7501443-B2March 10, 2009Ranbaxy Laboratories LimitedFlavaxate derivatives as muscarinic receptor antagonists
    US-7517905-B2April 14, 2009Ranbaxy Laboratories LimitedSubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    US-7544708-B2June 09, 2009Ranbaxy Laboratories LimitedAzabicyclo derivatives as muscarinic receptor antagonists
    US-7560479-B2July 14, 2009Ranbaxy Laboratories Limited3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    US-7592359-B2September 22, 2009Ranbaxy Laboratories LimitedSubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    US-7612084-B2November 03, 2009Pfizer IncAmine derivatives for the treatment of asthma and COPD
    US-7670612-B2March 02, 2010Innercap Technologies, Inc.Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
    US-7855230-B2December 21, 2010Ucb Pharma GmbhDerivatives of 3,3-diphenylpropylamines
    US-7985772-B2July 26, 2011Ucb Pharma GmbhDerivatives of 3,3-diphenylpropylamines
    US-7989654-B2August 02, 2011Ucb Pharma GmbhHigh purity bases of 3,3-diphenylpropylamino monoesters
    US-8193391-B2June 05, 2012Lek Pharmaceuticals, D.D.Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines
    US-8338478-B2December 25, 2012Ucb Pharma GmbhDerivatives of 3,3-diphenylpropylamines
    US-8361497-B2January 29, 2013Innercap Technologies, Inc.Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same
    WO-03039464-A2May 15, 2003Pharmacia & Upjohn CompanyAntimuscarinic aerosol
    WO-03039464-A3February 26, 2004Sue K Cammarata, Karen Kolbasa, Joe Palandra, Ivan Richards, Upjohn Co, Mark P WarcholAntimuscarinic aerosol
    WO-2004014363-A1February 19, 2004Ranbaxy Laboratories LimitedDerives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
    WO-2004078700-A1September 16, 2004Ranbaxy Laboratories LimitedDerives de 3,3-diarylpropylamine et procedes permettant de les isoler
    WO-2004089281-A2October 21, 2004Hetero Drugs LimitedNouveaux corps polymorphes de tartrate de tolterodine
    WO-2004089281-A3December 02, 2004Hetero Drugs Ltd, Reddy Dasari Muralidhara, Reddy Bandi Parthasaradhi, Reddy Rapolu Raji, Reddy Kura Rathnakar, Chander Reddy Kesireddy SubashNouveaux corps polymorphes de tartrate de tolterodine
    WO-2007039918-A1April 12, 2007Natco Pharma LimitedNovel process for the preparation of tolterodine
    WO-2007045979-A1April 26, 2007Ranbaxy Laboratories LimitedPharmaceutical compositions of muscarinic receptor antagonists
    WO-2007072169-A2June 28, 2007Pfizer Products Inc.Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
    WO-2007072169-A3November 01, 2007Carl Erik Johan Mastrell, Pfizer Prod Inc, Michael Allen SuessermanCombinaison pharmaceutique utilisee pour traiter des troubles urinaires du bas appareil (tuba)
    WO-2008017278-A3July 10, 2008Zentiva As, Martin Svoboda, Josef Jampilek, Martina Kacirkova, Vaclav Tomasek, Mikulas Lehocky, Ludmila Hejtmankova, Vaclav VosatkaCrystalline tolterodine tartarate and a pharmaceutical composition containing the same
    WO-9717330-A1May 15, 1997Smithkline Beecham CorporationProcess
    WO-9829402-A1July 09, 1998Pharmacia & Upjohn CompanyProcess to prepare tolterodine